Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Jahanzeb

Medical Oncology Boca Raton, FL Medical Doctor

NPI 1114919503 CMS profile 186935

2155 W Maya Palm Dr, Boca Raton, FL 33432

Open in the dashboard

General payments

$1,276,730

1,342 records reported · program years 2019–2025

Research payments

$2,011

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$171,422 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Mohammad Jahanzeb of Boca Raton, FL is reported in the CMS Open Payments database as having received $1,276,730 across 1,342 general payments and $2,011 in research payments paid to them. Separately, studies naming them as principal investigator received $171,422 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $205,726 115
2024 General $316,575 199
2023 General $220,976 238
2022 General $250,505 227
2021 General $111,873 236
2021 Research $2,011 2
2020 General $85,510 182
2019 General $85,565 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Jahanzeb
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Mohammad Jahanzeb were reported at $205,726. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Mohammad Jahanzeb Medical Oncology median Middle half National median
2019 $85,565 $968 $140–$6,658 $163
2020 $85,510 $747 $102–$5,891 $114
2021 $111,873 $430 $50–$4,098 $132
2022 $250,505 $812 $127–$4,907 $149
2023 $220,976 $957 $144–$5,248 $160
2024 $316,575 $1,042 $149–$5,650 $164
2025 $205,726 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $335,612 160 payments
  2. AstraZeneca Pharmaceuticals LP $245,607 221 payments
  3. Daiichi Sankyo Inc. $147,425 113 payments
  4. Regeneron Healthcare Solutions, Inc. $140,701 114 payments
  5. Merck Sharp & Dohme Corporation $131,707 136 payments
  6. Gilead Sciences, Inc. $65,653 54 payments
  7. Bard Peripheral Vascular, Inc. $31,460 5 payments
  8. Novocure Inc. $29,412 44 payments
  9. Novartis Pharmaceuticals Corporation $25,584 31 payments
  10. AbbVie, Inc. $18,806 7 payments
  11. Other $104,762 457 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $773,969 201 payments
  2. Consulting Fee $269,484 102 payments
  3. Travel and Lodging $172,611 337 payments
  4. Food and Beverage $28,666 690 payments
  5. Grant $17,250 2 payments
  6. Honoraria $14,382 6 payments
  7. Debt forgiveness $278 1 payment
  8. Education $89 3 payments
Products named General payments · program years 2019–2025
  1. ALUNBRIG Oncology $206,179 96 payments
  2. LIBTAYO $143,290 118 payments
  3. ENHERTU Oncology $138,499 102 payments
  4. KEYTRUDA $104,812 107 payments
  5. EXKIVITY $91,867 38 payments
  6. ENHERTU Oncology $86,040 58 payments
  7. Trodelvy $65,383 50 payments
  8. LYNPARZA $28,906 20 payments
  9. IMFINZI $27,802 27 payments
  10. ALUNBRIG Oncology $27,418 13 payments
  11. Other $182,624 691 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,187 1 payment
  2. F. Hoffmann-La Roche AG $824 1 payment

Records

1,344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record